1. To understand the biological and societal causes of for the disproportionate burden of cancer among ethnically diverse populations for the development of strategies to eliminate cancer disparities;
  2. To identify cancer predisposition genes in ethnically diverse populations for the development of genomic strategies that will identify those at highest risk for cancer and develop prevention strategies in high-risk groups and individuals;
  3. To identify molecular changes in tumors that may serve as targets for treatment, thereby reducing normal tissue toxicity and improving quality of life in cancer patients;
  4. To collaborate with community members, clinicians and scientists to disseminate the knowledge about cancer  research and its opportunities. 

We have a number of clinical trials and research studies that need you!

          Cancer treatment has relied on very toxic drugs that affect both tumors and, most times, normal tissue. To date, molecular markers that predict the benefit of a specific drug or help us understand drug resistance in the clinic have been lacking.  Furthermore, African Americans continue to suffer disproportionately due to higher rates of cancer and being diagnosed with more deadly cancers.  One of the proposed solutions to these problems is to use genomics to identify and target the weaknesses in individual cancers. 


          On January 30, 2015, President Obama announced the Precision Medicine Initiative (PMI).  Precision medicine is defined as interventions that prevent, diagnose, or treat disease based on the molecular understanding and pathology of the disease, as well as the individual with the disease.  The PMI will accelerate biomedical research and provide clinicians with new tools and cancer therapies to select which treatments will work best for which patients. As such, the Hampton University Cancer Research Center (HUCRC) is using the tenets of precision medicine to enhance the understanding of the molecular mechanisms of cancer, advance and accelerate genomics science and technology development, and efficiently translate the genomics data to improve cancer prevention, early detection, diagnosis and treatment.  To improve the lives of individuals with cancer, we have embarked on a research initiative to use cutting edge genetics and technology to interrogate the fundamental genetic code responsible for cancer development and overall clinical behavior. Cancer is a direct result of the genetic changes in its genome. Along these lines, our research group is pursuing fundamental questions regarding the underlying genetics of cancer risk, cancer recurrence and the response of cancers to specific targeted therapies. 

Research Initiatives:

   "Tonight, I’m launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer

    and diabetes — and to give all of us access to the personalized information we need to keep ourselves and

   our families healthier.” – United States President Barack Obama during his  State of the Union address

   on January 20, 2015.